Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cervomed Inc (CRVO)

Cervomed Inc (CRVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,360
  • Shares Outstanding, K 9,253
  • Annual Sales, $ 9,740 K
  • Annual Income, $ -16,290 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta -0.89
  • Price/Sales 10.94
  • Price/Cash Flow N/A
  • Price/Book 2.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.79
  • Number of Estimates 3
  • High Estimate -0.74
  • Low Estimate -0.86
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +1.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.90 +5.51%
on 01/15/26
8.55 -14.85%
on 12/24/25
-1.07 (-12.81%)
since 12/16/25
3-Month
6.56 +10.90%
on 11/11/25
10.00 -27.20%
on 11/28/25
-0.32 (-4.21%)
since 10/16/25
52-Week
1.92 +279.17%
on 03/11/25
16.94 -57.02%
on 03/21/25
+5.17 (+245.02%)
since 01/16/25

Most Recent Stories

More News
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker...

CRVO : 7.28 (+2.82%)
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to...

CRVO : 7.28 (+2.82%)
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating...

CRVO : 7.28 (+2.82%)
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b...

CRVO : 7.28 (+2.82%)
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advancing...

CRVO : 7.28 (+2.82%)
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional,...

CRVO : 7.28 (+2.82%)
CervoMed to Present at the Emerging Growth Conference

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today...

CRVO : 7.28 (+2.82%)
CervoMed (CRVO) Receives a Buy from Canaccord Genuity

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on CervoMed, with a price target of $27.00. The company’s shares closed yesterday at $8.22.Elevate Your...

CRVO : 7.28 (+2.82%)
CervoMed Unveils Promising Phase 2b Trial Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

CRVO : 7.28 (+2.82%)
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood...

CRVO : 7.28 (+2.82%)

Business Summary

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase...

See More

Key Turning Points

3rd Resistance Point 7.94
2nd Resistance Point 7.67
1st Resistance Point 7.48
Last Price 7.28
1st Support Level 7.02
2nd Support Level 6.75
3rd Support Level 6.56

See More

52-Week High 16.94
Fibonacci 61.8% 11.20
Fibonacci 50% 9.43
Fibonacci 38.2% 7.66
Last Price 7.28
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar